Access cutting-edge chronic kidney diseases treatment through this early phase 1 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Chicago location
Preparing your pre-screening questions…
Access chronic kidney diseases specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic kidney diseases treatment provided free
Check if you qualify for this chronic kidney diseases clinical trial in Chicago, IL
No-Cost Study Care
Local to Chicago
Convenient for IL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are: 1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)? 2. Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests? Participants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care. Study Procedures Include * For participants randomly selected for treatment, take empagliflozin once daily for 3 months * Phone calls with researchers every 2 weeks for check-ins * For participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests * All study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Yes, this clinical trial (NCT06430684) has an active research site in Chicago, IL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for chronic kidney diseases treatment options in Chicago, IL, this clinical trial (NCT06430684) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced chronic kidney diseases specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all chronic kidney diseases clinical trials near you to find additional studies recruiting in your area.
See all ankylosing spondylitis clinical trials recruiting in Chicago — not just this study.
Browse Ankylosing Spondylitis Trials in Chicago →